CD19+CD22 DUAL-TARGET CAR-T
FOR B-CELL ALL
When tumour cells escape by losing CD19, dual-targeting adds CD22 as a second lock — making it far harder for ALL to hide from the immune system.
analyticsAt a Glance
- check_circleCD19-negative relapse occurs in 20–40% of ALL patients after single CD19 CAR-T — the most common resistance mechanism
- check_circleDual CD19+CD22 CAR-T requires the tumour to simultaneously lose both antigens to escape — a much less likely event
- check_circleChinese academic centres have published the largest CD19+CD22 dual-CAR-T ALL series globally
- check_circleCancerFax connects patients with Chinese centres developing and delivering dual-target ALL CAR-T protocols
The Antigen Escape Problem in B-Cell ALL
Single-target CD19 CAR-T therapy produces high remission rates in r/r B-cell ALL — but relapse remains a major challenge. The most common mechanism of relapse is antigen escape: tumour cells downregulate or lose CD19 expression, becoming invisible to CD19-directed CAR-T cells. CD19-negative relapse occurs in approximately 20–40% of patients who relapse after CD19 CAR-T, leaving them without a CAR-T-based salvage option if only CD19-directed products are available.
“A single lock on a door can be picked. Two locks — particularly on two different biological pathways — make escape exponentially harder.”
Why CD19 Is Lost After CAR-T
Under intense immune pressure from CD19-directed CAR-T cells, ALL blasts can escape by several mechanisms: loss of the CD19 gene, alternative splicing producing a CAR-T-resistant CD19 isoform, lineage switch (B-to-myeloid), or selection of pre-existing CD19-dim subclones. All mechanisms share the same result — the tumour becomes invisible to CD19-directed immune surveillance.
Why CD22 Is the Right Second Target
CD22 is expressed on B-cell ALL blasts independently of CD19 — allowing it to function as a true orthogonal target. CD22 expression is maintained even in CD19-dim or CD19-negative ALL blasts in most cases. CD22 CAR-T monotherapy has also shown activity in r/r ALL, confirming it is a therapeutically valid target independently of CD19.
Dual-Target CD19+CD22 CAR-T: Key Clinical Numbers
Published data from Chinese academic centre series establishes the efficacy and antigen-escape prevention profile of CD19+CD22 dual-target constructs.
- 20–40%CD19-negative antigen escape relapse rate after single-target CD19 CAR-T in B-ALLThe frequency of CD19-negative relapse — the mechanism dual-targeting is specifically designed to prevent — in patients relapsing after single CD19-directed CAR-T.
- 85–93%MRD-negative CR rate with CD19+CD22 dual-target CAR-T in published Chinese seriesPublished series from Ruijin Hospital and PKUPH demonstrate MRD-negative complete remission rates of 85–93% with CD19+CD22 dual-target constructs — consistent with or slightly exceeding single-target CD19 CR rates.
- <5%Antigen-loss relapse (both CD19 and CD22 simultaneously lost) in dual-target respondersSimultaneous loss of both CD19 and CD22 — the event required for dual-target escape — occurs far less frequently than single CD19 loss, validating the therapeutic rationale for dual targeting.
Dual-Target CAR-T Construct Designs: How They Work
Several engineering strategies exist for combining CD19 and CD22 targeting in a single CAR-T product — each with distinct characteristics and potential clinical trade-offs.
| Design | How It Works | Advantage | Potential Trade-Off |
|---|---|---|---|
| Tandem CAR (TanCAR) | Single CAR receptor contains both CD19 and CD22 binding domains in tandem — recognises either antigen with the same T cell | Both targets on one receptor — simpler manufacturing; T cell attacks when either CD19 or CD22 is present | Bridging sequence between domains may reduce binding affinity for each individual target vs separate CARs |
| Bicistronic CAR | Single construct encodes two separate CARs (one CD19, one CD22) expressed on the same T cell via 2A or IRES linker | Each CAR retains its full individual affinity; both expressed on same cell | Larger transgene; potentially lower expression level for each individual CAR |
| Dual transduction (two products mixed) | CD19 CAR-T and CD22 CAR-T manufactured separately and mixed before infusion | Each product optimised independently; ratio can be adjusted | Two GMP manufacturing runs; more complex logistics; T cells from one product may outcompete the other in vivo |
| Cotransduced with two CARs (CRISPR or lentiviral dual) | Single T cell receives two separate CAR transgenes — expresses both CD19 CAR and CD22 CAR simultaneously | Both CARs on same cell — most immunologically elegant; T cell simultaneous engagement possible | CRISPR editing adds manufacturing complexity; currently primarily investigational |
When Is Dual-Target CD19+CD22 CAR-T Most Appropriate?
Dual-target CAR-T is most valuable in specific clinical scenarios — understanding when to use it rather than single-target therapy helps patients and clinicians select the right approach.
- 1
CD19-Negative Relapse After Prior CD19 CAR-T
The primary indication for CD22 (or dual) CAR-T. Patients who relapse with CD19-negative ALL after prior CD19-directed CAR-T have no CD19 antigen to target — CD22-directed or dual-target therapy is the only CAR-T option in this scenario.
- 2
High-Risk ALL Where Antigen Escape Concern Drives Upfront Dual Targeting
Some Chinese centres are using dual CD19+CD22 CAR-T as a first CAR-T treatment in high-risk ALL — particularly in patients with dim CD19 expression (low density), Philadelphia-like ALL, or mixed-phenotype acute leukaemia — where CD19 loss risk is considered higher than average.
- 3
Relapsed/Refractory ALL with Heterogeneous CD19 Expression
When flow cytometry shows heterogeneous CD19 expression — some blasts CD19+, others CD19-dim — dual-target therapy covers the CD19-dim population that single CD19 CAR-T may not efficiently eliminate.
- 4
Post-CD19 CAR-T Relapse with CD19+ Disease (Sequential CD22 Strategy)
Even when CD19 expression is retained at relapse after CD19 CAR-T, the T cells from the first infusion may be exhausted or insufficient. CD22 CAR-T alone or dual CD19+CD22 provides a fresh immune attack with a distinct target.
Single CD19 CAR-T vs Dual CD19+CD22 CAR-T: Clinical Differences
Choosing between single and dual-target CAR-T in ALL requires weighing antigen escape risk against manufacturing considerations and available evidence.
Single CD19 CAR-T
- Largest evidence base — FDA/NMPA approvedTisagenlecleucel, relma-cel, and axicabtagene are fully approved with mature 5+ year long-term data in paediatric and adult ALL — the most thoroughly characterised CAR-T products available.
- Simpler manufacturing — faster accessSingle-target manufacturing is a well-established GMP process — fewer technical constraints, faster turnaround, and more manufacturing sites than newer dual-target constructs.
- Appropriate for most first-CAR-T ALL patientsFor patients who have not previously received CAR-T and have uniform CD19 expression, single-target CD19 CAR-T remains the established first choice at most centres globally.
Dual CD19+CD22 CAR-T
- Dramatically reduces antigen-loss relapseRequires simultaneous loss of both CD19 and CD22 for escape — a far less frequent event than single CD19 loss. Published Chinese series show <5% dual-antigen-loss relapse vs 20–40% CD19-single-loss relapse.
- Only CD19-covering option after CD19-negative relapseFor patients who have already lost CD19, dual-target therapy with a CD22-containing construct is the only way to offer any CD19-axis coverage alongside CD22-directed killing.
- Available at Chinese centres — investigational elsewhereCD19+CD22 dual-target constructs are primarily available through Chinese clinical trials and academic protocols — not yet commercially approved in the USA or Europe. Access is facilitated through CancerFax.
Frequently Asked Questions
Common questions about dual-target CD19+CD22 CAR-T from ALL patients and families.
About Dual-Target CAR-T for ALL
Can I receive CD19+CD22 dual CAR-T if I have already had CD19 CAR-T?
Yes — and this is one of the primary indications. If you relapsed after CD19 CAR-T with CD19-negative disease, the CD22 component of a dual-target construct provides genuine tumour-cell killing activity even though CD19 is absent. If you relapsed with CD19-positive disease, the dual-target construct offers a fresh immune attack against both antigens with newly manufactured, non-exhausted T cells. Eligibility depends on your residual CD22 expression — confirm by flow cytometry from a current bone marrow biopsy.
Is CD22 expression always maintained after CD19 loss?
In most cases, yes — CD22 is expressed independently of CD19 and is maintained on CD19-negative escape clones in the majority of patients. However, CD22 expression should be confirmed by flow cytometry from a biopsy obtained after CD19-negative relapse, not assumed. CD22 expression can vary in density — low-density CD22 may reduce dual-target efficacy and is an important consideration in eligibility assessment.
Where is CD19+CD22 dual-target CAR-T available?
Dual CD19+CD22 CAR-T is primarily available through clinical trial protocols at Chinese academic centres — including Ruijin Hospital (Shanghai Jiao Tong University) and PKUPH (Beijing). These centres have published the largest dual-target ALL CAR-T series globally and have established manufacturing capabilities for these constructs. CancerFax coordinates eligibility review and access to these programmes for international patients.
How do outcomes with dual-target compare to single-target CAR-T in ALL?
MRD-negative CR rates with CD19+CD22 dual-target constructs in published Chinese series are 85–93% — comparable to best-in-class single CD19 CAR-T. The primary advantage is not a higher initial response rate but a lower rate of antigen-escape relapse — reducing the frequency of the most difficult post-CAR-T relapse scenario. Long-term survival data with bridge transplant following dual-target CAR-T is accumulating and shows outcomes consistent with single-target series.
More from the CAR-T Cell Therapy Resource Library
Continue exploring CAR-T guides — from haploidentical transplant bridging to DLBCL and myeloma.
- ↑ CAR-T Cell Therapy — Complete Guide
- CAR-T for Relapsed/Refractory B-Cell ALL in China
- CAR-T as Bridge to Haploidentical Transplant: PKUPH Approach
- CD19 vs BCMA vs GPRC5D: What These Targets Mean
- The CAR-T Treatment Timeline: Leukapheresis to Discharge
- Second Opinions for Blood Cancers: Ruijin Hospital and Peking University
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Access Dual-Target CAR-T for ALL Through CancerFax
CancerFax reviews your ALL treatment history and CD19/CD22 expression status to assess eligibility for dual-target CAR-T — including access to Chinese centres running CD19+CD22 protocols for patients who have relapsed after single-target CD19 therapy.
This content is for informational purposes only. CAR-T eligibility must be assessed by a qualified haematologist at an experienced centre.